SynthesisFuture oncology (London, England)2025
The benefits and pitfalls of adding bevacizumab to neoadjuvant chemotherapy for advanced ovarian cancer: a meta-analysis.
Synthesis in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo appraise the efficacy and toxicity of adding bevacizumab to neoadjuvant chemotherapy (NACT) for advanced-stage ovarian cancer (AOC).
methodAll studies regarding neoadjuvant bevacizumab for AOC published in PubMed, EMBASE, Scopus and Web of Science from 1 November 2010 to 31 December 2024 were retrieved and reviewed.
resultsThree randomized clinical trials, five retrospective cohort studies, and six case series were eligible, including 687 patients receiving bevacizumab-NACT and 1482 patients receiving standard-NACT. There were no significant differences between the bevacizumab-NACT group and the standard-NACT group in the rates of interval debulking surgery implementation, achieving complete cytoreduction, wound complication, thrombogenesis, and infections (grade ≥3). The rate of achieving optimal cytoreduction in bevacizumab-NACT group was significantly higher than that in standard-NACT group (RR: 1.17, 95% CI: 1.02 to 1.34, P = 0.02; I
conclusionAdding bevacizumab to NACT for AOC can enhance the feasibility of optimal cytoreduction, rather than complete cytoreduction. However, bevacizumab-NACT increased the risk of gastrointestinal perforation. PROTOCOL REGISTRATION: www.crd.york.ac.uk/prospero identifier is CRD42024566484.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.